Literature DB >> 28939389

Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance.

Raffaela Campana1, Huey-Jy Huang1, Raphaela Freidl1, Birgit Linhart1, Susanne Vrtala1, Thomas Wekerle2, Alexander Karaulov3, Rudolf Valenta4.   

Abstract

Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing allergens or allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined allergen molecules and/or allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined recombinant allergens/allergen derivatives and allergen-derived synthetic peptides from the most common allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Allergen; Allergen-specific immunotherapy; Allergy; Allergy prevention; Oral tolerance induction; Recombinant allergen; T cell peptides

Mesh:

Substances:

Year:  2017        PMID: 28939389     DOI: 10.1016/j.smim.2017.08.017

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  12 in total

Review 1.  Modified Allergens for Immunotherapy.

Authors:  Pattraporn Satitsuksanoa; Anna Głobińska; Kirstin Jansen; Willem van de Veen; Mübeccel Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-16       Impact factor: 4.806

2.  Detection of IgE Reactivity to a Handful of Allergen Molecules in Early Childhood Predicts Respiratory Allergy in Adolescence.

Authors:  Magnus Wickman; Christian Lupinek; Niklas Andersson; Danielle Belgrave; Anna Asarnoj; Marta Benet; Mariona Pinart; Sandra Wieser; Judith Garcia-Aymerich; Alexandra Baar; Göran Pershagen; Angela Simpson; Inger Kull; Anna Bergström; Erik Melén; Carl Hamsten; Josep M Antó; Jean Bousquet; Adnan Custovic; Rudolf Valenta; Marianne van Hage
Journal:  EBioMedicine       Date:  2017-11-14       Impact factor: 8.143

Review 3.  Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches.

Authors:  Mirela Curin; Musa Khaitov; Alexander Karaulov; Leyla Namazova-Baranova; Raffaela Campana; Victoria Garib; Rudolf Valenta
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-09       Impact factor: 4.806

Review 4.  Recombinant allergens for immunotherapy: state of the art.

Authors:  Yury Zhernov; Mirela Curin; Musa Khaitov; Alexander Karaulov; Rudolf Valenta
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-08

Review 5.  DNA and mRNA vaccination against allergies.

Authors:  Sandra Scheiblhofer; Josef Thalhamer; Richard Weiss
Journal:  Pediatr Allergy Immunol       Date:  2018-09-20       Impact factor: 6.377

Review 6.  Novel vaccines targeting dendritic cells by coupling allergoids to mannan.

Authors:  Cristina Benito-Villalvilla; Irene Soria; José Luis Subiza; Oscar Palomares
Journal:  Allergo J Int       Date:  2018-05-18

Review 7.  Molecular Approaches for Diagnosis, Therapy and Prevention of Cow´s Milk Allergy.

Authors:  Birgit Linhart; Raphaela Freidl; Olga Elisyutina; Musa Khaitov; Alexander Karaulov; Rudolf Valenta
Journal:  Nutrients       Date:  2019-06-29       Impact factor: 5.717

8.  A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens.

Authors:  Huey-Jy Huang; Mirela Curin; Srinita Banerjee; Kuan-Wei Chen; Tetiana Garmatiuk; Yvonne Resch-Marat; Claudia Carvalho-Queiroz; Katharina Blatt; Guro Gafvelin; Hans Grönlund; Peter Valent; Raffaela Campana; Margarete Focke-Tejkl; Rudolf Valenta; Susanne Vrtala
Journal:  Allergy       Date:  2019-10-03       Impact factor: 13.146

9.  Resistance of parvalbumin to gastrointestinal digestion is required for profound and long-lasting prophylactic oral tolerance.

Authors:  Raphaela Freidl; Antonia Gstöttner; Ulrike Baranyi; Ines Swoboda; Frank Stolz; Margarete Focke-Tejkl; Thomas Wekerle; Ronald van Ree; Rudolf Valenta; Birgit Linhart
Journal:  Allergy       Date:  2019-10-03       Impact factor: 13.146

Review 10.  Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?

Authors:  Inna Tulaeva; Bernhard Kratzer; Raffaela Campana; Mirela Curin; Marianne van Hage; Antonina Karsonova; Ksenja Riabova; Alexander Karaulov; Musa Khaitov; Winfried F Pickl; Rudolf Valenta
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.